MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

Thomas Powles, Joseph P. Eder, Gregg Fine, +12

Nature

UrologyOncologyGenitourinary CancerMedicineCancer Treatment +3

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

Arjun Vasant Balar, Matthew D. Galsky, Jonathan E. Rosenberg, +32

The Lancet

UrologyGenitourinary CancerMedicineFirst-line TreatmentCancer Treatment +5

<i>In vivo</i> Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models

Klaus P. Hoeflich, Carol O’Brien, Zachary Boyd, +14

Clinical Cancer Research

Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma

Bruno Sangro, Ignacio Melero, Samir Wadhawan, +12

Journal of Hepatology

TRPS1 Targeting by miR-221/222 Promotes the Epithelial-to-Mesenchymal Transition in Breast Cancer

Susanna Stinson, Mark R. Lackner, Alex Adai, +17

Science Signaling

Tumor BiologySystems BiologyBreast OncologyMir-221/222 PromotesTrps1 Targeting +11

Pro- and Antiinflammatory Cytokine Signaling: Reciprocal Antagonism Regulates Interferon-gamma Production by Human Natural Killer Cells

Jianhua Yu, Wei Min, Brian Becknell, +15

Immunity

InflammationCytokineInterferon-gamma ProductionAutoimmune DiseaseInnate Immune System +10

Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab

Bharathi Vennapusa, Brian M. Baker, Marcin Kowanetz, +17

Applied immunohistochemistry & molecular morphology

ImmunologyImmunoeditingPathologyImmunotherapyTumor Biology +14

miR-221/222 Targeting of Trichorhinophalangeal 1 (TRPS1) Promotes Epithelial-to-Mesenchymal Transition in Breast CancerA presentation from the Keystone Symposium on Epithelial Plasticity and Epithelial to Mesenchymal Transition, Vancouver, Canada, 21 to 26 January 2011. This Presentation also complements the <i>Science Signaling</i> Research Article by Stinson <i>et al.</i> published 14 June 2011.

Susanna Stinson, Mark R. Lackner, Alex Adai, +17

Science Signaling

Current Status of Companion and Complementary Diagnostics: Strategic Considerations for Development and Launch

Heleen Scheerens, A Malong, K Bassett, +13

Clinical and Translational Science

Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC)

Heinz‐Josef Lenz, Eric Van Cutsem, María Luisa Limón, +15

Annals of Oncology

Low-dose IpilimumabMedicineImmunologyColorectal CancerPathology +6